1. Home
  2. RERE vs EVO Comparison

RERE vs EVO Comparison

Compare RERE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATRenew Inc.

RERE

ATRenew Inc.

HOLD

Current Price

$5.12

Market Cap

996.7M

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.86

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RERE
EVO
Founded
2011
1993
Country
China
Germany
Employees
2389
4553
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
996.7M
934.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RERE
EVO
Price
$5.12
$2.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
792.2K
91.4K
Earning Date
05-19-2026
04-08-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.70
$1.37
Revenue Next Year
$22.93
$10.05
P/E Ratio
$34.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$2.31
52 Week High
$6.47
$4.80

Technical Indicators

Market Signals
Indicator
RERE
EVO
Relative Strength Index (RSI) 61.64 46.32
Support Level $4.18 $2.63
Resistance Level $5.20 $3.78
Average True Range (ATR) 0.24 0.09
MACD 0.07 -0.04
Stochastic Oscillator 94.97 33.38

Price Performance

Historical Comparison
RERE
EVO

About RERE ATRenew Inc.

ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: